Treatment of Severe Pneumonia

Initial Antibiotic Therapy

The American Thoracic Society recommends parenteral antibiotics should be administered immediately after diagnosis to ensure prompt, high blood and lung concentrations 1
For ICU or intermediate care patients with severe CAP without risk factors for Pseudomonas aeruginosa, the Infectious Diseases Society of America suggests using a non-antipseudomonal cephalosporin III + macrolide OR moxifloxacin or levofloxacin ± non-antipseudomonal cephalosporin III 2
For patients with risk factors for P. aeruginosa, the European Respiratory Society recommends using an antipseudomonal cephalosporin OR acylureidopenicillin/β-lactamase inhibitor OR carbapenem (meropenem preferred) PLUS ciprofloxacin OR macrolide + aminoglycoside 2

Combination therapy provides coverage for both typical and atypical pathogens, particularly Legionella sp., according to the American College of Chest Physicians 1
Evidence indicates combination therapy is associated with better outcomes in severe pneumonia, with a strength of evidence rated as high by the National Institutes of Health 1
This approach ensures coverage against the most common pathogens including Streptococcus pneumoniae, Staphylococcus aureus, and less common but high-mortality Gram-negative organisms, as recommended by the Centers for Disease Control and Prevention 1

The Infectious Diseases Society of America recommends considering MRSA in patients hospitalized within the last few months 1
For nosocomial pneumonia caused by P. aeruginosa, the European Respiratory Society suggests adding an aminoglycoside to the regimen 1
In patients at risk of gram-negative enteric bacteria with extended-spectrum β-lactamase, the American Thoracic Society recommends using ertapenem when P. aeruginosa is not a concern 2

For severe microbiologically undefined pneumonia, the American College of Chest Physicians recommends 10 days of treatment 1, 3
Extended treatment (14-21 days) is recommended for Legionella pneumonia, Staphylococcal pneumonia, and Gram-negative enteric bacilli pneumonia by the Infectious Diseases Society of America 1, 3
Generally, treatment should not exceed 8 days in a responding patient, according to the European Respiratory Society 2

The American Thoracic Society recommends switching to oral therapy when clinical improvement is evident, temperature has been normal for 24 hours, and no contraindications to oral administration exist 1
Sequential treatment should be considered in all hospitalized patients except the most severely ill, as suggested by the European Respiratory Society 2

The American Thoracic Society recommends early mobilization for all patients 2
Low molecular weight heparin should be given in patients with acute respiratory failure, according to the European Respiratory Society 2
Non-invasive ventilation can be considered, particularly in patients with COPD and ARDS, as recommended by the American College of Chest Physicians 2

Response should be monitored using simple clinical criteria, including body temperature, respiratory parameters, and hemodynamic parameters, as suggested by the American College of Chest Physicians 1, 2, 3
C-reactive protein should be measured on days one and three/four, especially in patients with unfavorable clinical parameters, according to the European Respiratory Society 2

If patient fails to improve, a thorough review by an experienced clinician of clinical history and examination, prescription chart, and results of all available investigations should be conducted, as recommended by the American Thoracic Society 1
Consider additional investigations, including repeat chest radiograph, CRP and white cell count, and further specimens for microbiological testing, as suggested by the Infectious Diseases Society of America 1, 3